HomeCompareMDXHF vs EQR

MDXHF vs EQR: Dividend Comparison 2026

MDXHF yields 4545.45% · EQR yields 5.87%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 MDXHF wins by $24684467220188.12M in total portfolio value
10 years
MDXHF
MDXHF
● Live price
4545.45%
Share price
$0.04
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$24684467220188.17M
Annual income
$23,660,503,792,881,107,000.00
Full MDXHF calculator →
EQR
EQR
● Live price
5.87%
Share price
$59.15
Annual div
$3.47
5Y div CAGR
15.8%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$47.8K
Annual income
$5,475.61
Full EQR calculator →

Portfolio growth — MDXHF vs EQR

📍 MDXHF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodMDXHFEQR
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, MDXHF + EQR cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
MDXHF pays
EQR pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

MDXHF
Annual income on $10K today (after 15% tax)
$386,363.64/yr
After 10yr DRIP, annual income (after tax)
$20,111,428,223,948,940,000.00/yr
EQR
Annual income on $10K today (after 15% tax)
$499.01/yr
After 10yr DRIP, annual income (after tax)
$4,654.27/yr
At 15% tax rate, MDXHF beats the other by $20,111,428,223,948,935,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of MDXHF + EQR for your $10,000?

MDXHF: 50%EQR: 50%
100% EQR50/50100% MDXHF
Portfolio after 10yr
$12342233610094.11M
Annual income
$11,830,251,896,440,556,000.00/yr
Blended yield
95.85%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on EQR right now

MDXHF
No analyst data
Altman Z
-81.2
Piotroski
3/9
EQR
Analyst Ratings
16
Buy
28
Hold
2
Sell
Consensus: Hold
Price Target
$70.35
+18.9% upside vs current
Range: $63.00 — $78.50
Altman Z
1.8
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

MDXHF buys
0
EQR buys
0
No recent congressional trades found for MDXHF or EQR in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricMDXHFEQR
Forward yield4545.45%5.87%
Annual dividend / share$2.00$3.47
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%15.8%
Portfolio after 10y$24684467220188.17M$47.8K
Annual income after 10y$23,660,503,792,881,107,000.00$5,475.61
Total dividends collected$24614959662391.29M$23.0K
Payment frequencyquarterlyquarterly
SectorStockREIT

Year-by-year: MDXHF vs EQR ($10,000, DRIP)

YearMDXHF PortfolioMDXHF Income/yrEQR PortfolioEQR Income/yrGap
1← crossover$465,245$454,545.45$11,380$679.82+$453.9KMDXHF
2$20,261,851$19,764,038.00$13,014$837.25+$20.25MMDXHF
3$826,111,319$804,431,138.78$14,961$1,036.20+$826.10MMDXHF
4$31,536,344,373$30,652,405,261.22$17,297$1,289.22+$31536.33MMDXHF
5$1,127,331,439,718$1,093,587,551,239.73$20,121$1,613.15+$1127331.42MMDXHF
6$37,741,323,559,434$36,535,078,918,935.74$23,561$2,030.84+$37741323.54MMDXHF
7$1,183,503,101,225,504$1,143,119,885,016,909.50$27,783$2,573.54+$1183503101.20MMDXHF
8$34,767,541,536,847,464$33,501,193,218,536,172.00$33,013$3,284.39+$34767541536.81MMDXHF
9$956,975,165,707,534,300$919,773,896,263,107,700.00$39,547$4,223.51+$956975165707.49MMDXHF
10$24,684,467,220,188,170,000$23,660,503,792,881,107,000.00$47,791$5,475.61+$24684467220188.12MMDXHF

MDXHF vs EQR: Complete Analysis 2026

MDXHFStock

MedX Health Corp, a medical device and software company, develops, manufactures, and markets skin related screening tools and phototherapy devices for pain relief and tissue repair in Canada, the United States, and internationally. The company offers SIAscopy, a medical device technology used to scan skin for suspicious moles and lesions; phototherapeutic medical devices, which use light energy in lower-level laser and LED to provide treatment for pain and tissue damage in the rehabilitation market; and SIAMETRICS, SIMSYS, and MoleMate, which creates real-time images for physicians and dermatologists to evaluate various types of moles or lesions within seconds. It operates DermSecure telemedicine platform that enables the web-based operation of its SIAscopy scanning technology and allows the company to deploy its technology in networks of third-party locations from which patients' mole and lesion images along with other relevant patient information can be connected to specialist physicians for remote assessment. The company was incorporated in 1999 and is headquartered in Mississauga, Canada.

Full MDXHF Calculator →

EQRREIT

Equity Residential is committed to creating communities where people thrive. The Company, a member of the S&P 500, is focused on the acquisition, development and management of residential properties located in and around dynamic cities that attract high quality long-term renters. Equity Residential owns or has investments in 305 properties consisting of 78,568 apartment units, located in Boston, New York, Washington, D.C., Seattle, San Francisco, Southern California and Denver.

Full EQR Calculator →
📬

Get this MDXHF vs EQR comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

MDXHF vs SCHDMDXHF vs JEPIMDXHF vs OMDXHF vs KOMDXHF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.